Posted by Michael Wonder on 18 Mar 2021
Kiniksa announces FDA approval of Arcalyst (rilonacept) for recurrent pericarditis
18 March 2021 - Kiniksa launches Kiniksa One Connect patient support program.
Kiniksa Pharmaceuticals today announced the U.S. FDA approved Arcalyst (rilonacept), a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1 alpha and interleukin-1 beta signalling, for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older.
The commercial launch is expected in April 2021.
